JA WP5 – Relative Effectiveness Assessment of Pharmaceuticals

JA WP5 – Relative Effectiveness Assessment of Pharmaceuticals

Objectives

  • To develop principles, methodological guidance as well as functional online tools and policies for REA by identifying areas where methodological guidance is needed and by providing it, suggesting ways to integrate REA of pharmaceuticals as a special version of the Core Model
  • To test and implement a REA group of pharmaceuticals in line with the core HTA development.

 

Deliverables

  • A methodological guidance that will be appropiate for the assessment of relative effectiveness of pharmaceuticals
  • A relative effectiveness assessment of a (group) of pharmaceutical(s)

 

See the full list of WP5 products

Partners

Lead Partner

ZIN

National Health Care Institute
(Zorginstituut Nederland)

Eekholt 4

NL-112XH Diemen

Netherlands

Telephone: +31 207979057

Fax: +31 (020) 797 8500

http://www.zorginstituutnederland.nl/

Co-Lead Partner

HAS

Associated Partners

AIFAGOEG, AustriaHVBIQWIGMoH CzechNIPHNO (formerly NOKC)SSD/MSOC, MaltaVEC, Latvia

Collaborating partners

AETSACAHTAIRF, DenmarkREGLOM-DSAN, ItalySNHTAUETS

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.